Bioavailability - Rapamycin

Rapamycin's bioavailability (in raw or simple solid form) is extremely low, typically ~1–2% oral bioavailability in humans.

This poor absorption is due to:

  • Poor aqueous solubility: Rapamycin is lipophilic and practically insoluble in water, limiting dissolution in the GI tract.
  • High molecular weight (~914 Da): Too large for passive diffusion through intestinal lining.
  • First-pass hepatic metabolism: Rapidly metabolized by CYP3A4 enzymes in the liver and intestines.
  • P-glycoprotein efflux substrate: Pumped back into the gut lumen by intestinal P-gp, reducing net absorption.

Why SMEDDS or Microemulsions Are Needed:

Without these, absorption is negligible, and the therapeutic effect would be unreliable or absent. This is why Rapamune (SMEDDS-based) was developed to raise it to a usable ~14% and allow oral administration in transplant patients and off-label longevity research.



🧠 Rapamycin Bioavailability: Route Comparison


Route	Approx. Bioavailability	Advantages	Challenges	Formulation Strategies


Oral (raw/standard)	~1–2%	Convenient	Poor solubility, extensive 1st-pass metabolism, P-gp efflux	None (base compound only)


Oral (SMEDDS / Rapamune)	~14%	Convenient, approved, reproducible	Still undergoes some 1st-pass metabolism	Microemulsion: solubilization, lymphatic absorption


Oral (Nanoformulations)	~10–20% (varies)	Potential for higher uptake	Stability, scale-up	Liposomes, solid lipid nanoparticles, nanocrystals


Sublingual / Buccal	~10–30% (theoretical)	Bypasses liver first-pass metabolism	Low water solubility, bitter taste, mucosal irritation	Ethanol-based sprays, cyclodextrin complexes, mucoadhesive gels


Transdermal (Topical)	<1% (unformulated) / ~5–10% (enhanced)	Bypasses GI/liver, localized delivery	Poor skin penetration (large molecule)	Ethosomes, transfersomes, nanoemulsions


Intranasal	~10–20% (theoretical)	Rapid absorption, avoids 1st-pass	Irritation, mucociliary clearance	Nanoemulsions, cyclodextrin-inclusion complexes


Rectal	~5–15% (est.)	Partial 1st-pass avoidance	Patient acceptability, formulation variability	Suppositories, lipid-based enemas

🧪 1. SMEDDS (Self-Microemulsifying Drug Delivery System) for Rapamycin

🧰 Materials Needed:

    1. Rapamycin (active drug)
    2. Oil phase: e.g., Capryol 90, Labrafac, or medium-chain triglycerides (MCT)
    3. Surfactant: e.g., Tween 80 (Polysorbate 80)
    4. Co-surfactant/co-solvent: e.g., Transcutol P, PEG 400, or ethanol
    5. Optional: Oleic acid (to help solubilize rapamycin), antioxidants (e.g., BHT)

🧪 Lab-Scale Procedure:

  • Determine solubility:
    • First, test rapamycin solubility in each excipient to choose optimal components (oil, surfactant, co-surfactant).
  • Prepare SMEDDS base:
    1. Mix selected oil (e.g., 10–30%), surfactant (40–60%), and co-surfactant (10–30%) in a beaker.
    2. Stir with a magnetic stirrer or vortex until clear.
  • Add rapamycin:
    1. Add rapamycin to the above mixture (1–2 mg/mL).
    2. Stir at 40–45°C until fully dissolved.
  • Self-emulsification test:
    1. Add 1 mL of formulation to 100 mL of water and stir gently.
    2. A clear or slightly bluish nanoemulsion should form in <1 minute.
    3. Filter sterilize (optional): Use 0.22 µm syringe filter for sterile formulations.
  • Storage:
    1. Store in amber vials, ideally under inert gas (e.g., nitrogen) at 4°C.

💊 Administration:

  • Can be encapsulated into soft gel capsules or taken as a liquid.

⚗️ 2. Oral Nanoformulations (e.g., Lipid Nanoparticles, Nanocrystals, or Polymeric Nanoparticles)

Typical approach using solid lipid nanoparticles (SLNs):

🧰 Materials Needed:

    1. Rapamycin
    2. Lipid: e.g., glyceryl behenate (Compritol), stearic acid
    3. Surfactant: e.g., Poloxamer 188, Tween 80
    4. Co-surfactant: optional (lecithin, bile salts)
    5. Aqueous phase: distilled water

🧪 Procedure: Hot Homogenization + Ultrasonication

  • Melt lipid: Heat lipid (e.g., 70–80°C) until fully melted.
  • Dissolve rapamycin: Add rapamycin to the molten lipid and stir.
  • Prepare aqueous surfactant phase: Dissolve surfactant (e.g., 1–2% w/v) in hot distilled water (same temp as lipid).
  • Emulsify: Add lipid-rapamycin melt into aqueous phase under high-speed homogenization (e.g., 10,000–20,000 rpm for 5–10 min).
  • Ultrasonication: Probe-sonicate the emulsion for 2–10 minutes in an ice bath to reduce particle size (target: ~100–200 nm).
  • Cooling: Let it cool to room temp. Lipid solidifies forming SLNs encapsulating rapamycin.
  • Characterization (optional): Measure particle size (DLS), zeta potential, and drug loading efficiency.

🧊 Storage:

  • Store at 4°C or lyophilize for long-term storage.



🧪 Summary Comparison:


Feature	SMEDDS	Nanoformulation (e.g., SLNs)


Size range	20–200 nm	50–300 nm


Requires heat	Mild (for mixing)	Yes (to melt lipids)


Bioavailability gain	~14%	10–20% (varies with formulation)


Scale-up friendly	Very	Moderate (more complex)


Stability	Good (self-emulsifies on demand)	Moderate (may need lyophilization)

  

📝 📜 ⏱️ ⬆️